Glenn Greenberg
Brave Warrior Advisors
Glenn Greenberg Elevance Health Inc stake
total: 103
Brave Warrior Advisors ELV trades
- Total transactions:
- 27
- New positions:
- 1
- Added:
- 10
- Reduced:
- 16
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Glenn Greenberg holds 1,122,308 Elevance Health Inc (ELV) shares with a market value of roughly $328.56M accounting for 8.13% of the overall portfolio. To date, the estimated cost basis is nearly $342.72 for "buy" trades and estimated average "sell" price is $401.09. Brave Warrior Advisors first purchased ELV in 2019 Q3, initially acquiring 638,397 shares. Since the initial investment in Elevance Health Inc (ELV), Brave Warrior Advisors has made 26 more transactions.
When did Glenn Greenberg buy Elevance Health Inc (ELV)?
Glenn Greenberg first invested in Elevance Health Inc (ELV) in 2019 Q3 at the reported quarter-end price of $240.10 per share.
What's the cost basis of Brave Warrior Advisors's ELV stake?
The estimated cost basis for Elevance Health Inc (ELV) stake is around $342.72 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $342.72
- Weighted AVG sell price:
- $401.09
Glenn Greenberg's historical trades in Elevance Health Inc
27 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
8.13%
|
1,122,308
|
$292.75
|
$328,555,667
|
-10.34% (-129,495)
|
-0.89%
|
|
2025 Q4
|
10.28%
|
1,251,803
|
$350.55
|
$438,819,542
|
-31.74% (-582,199)
|
-4.74%
|
|
2025 Q3
|
13.76%
|
1,834,002
|
$323.12
|
$592,602,726
|
+65.28% (+724,349)
|
+5.43%
|
|
2025 Q2
|
9.89%
|
1,109,653
|
$388.96
|
$431,610,631
|
-29.66% (-467,917)
|
-4.17%
|
|
2025 Q1
|
15.72%
|
1,577,570
|
$434.96
|
$686,179,847
|
-3.22% (-52,407)
|
-0.57%
|
|
2024 Q4
|
14.96%
|
1,629,977
|
$368.90
|
$601,298,515
|
-0.70% (-11,436)
|
-0.09%
|
|
2024 Q3
|
17.71%
|
1,641,413
|
$520.00
|
$853,534,760
|
+0.51% (+8,286)
|
+0.09%
|
|
2024 Q2
|
19.61%
|
1,633,127
|
$541.86
|
$884,926,196
|
-0.77% (-12,710)
|
-0.14%
|
|
2024 Q1
|
17.85%
|
1,645,837
|
$518.54
|
$853,432,318
|
-6.31% (-110,816)
|
-1.37%
|
|
2023 Q4
|
19.76%
|
1,756,653
|
$471.56
|
$828,367,289
|
+7.93% (+129,055)
|
+1.45%
|
|
2023 Q3
|
17.69%
|
$435.42
|
+23.18% (+306,326)
|
|||
|
2023 Q2
|
15.51%
|
$444.29
|
+21.80% (+236,504)
|
|||
|
2023 Q1
|
15.43%
|
$459.81
|
+24.34% (+212,353)
|
|||
|
2022 Q4
|
14.10%
|
$512.97
|
-26.68% (-317,456)
|
|||
|
2022 Q3
|
18.68%
|
$454.24
|
-1.77% (-21,405)
|
|||
|
2022 Q2
|
20.07%
|
$482.58
|
-10.49% (-141,973)
|
|||
|
2022 Q1
|
19.61%
|
$491.22
|
-0.92% (-12,536)
|
|||
|
2021 Q4
|
20.17%
|
$463.54
|
-0.40% (-5,477)
|
|||
|
2021 Q3
|
17.90%
|
$372.80
|
+19.72% (+225,846)
|
|||
|
2021 Q2
|
15.01%
|
$381.80
|
-1.57% (-18,313)
|
|||
|
2021 Q1
|
13.64%
|
$358.95
|
+50.91% (+392,594)
|
|||
|
2020 Q4
|
9.11%
|
$321.09
|
+0.94% (+7,208)
|
|||
|
2020 Q3
|
9.16%
|
$268.59
|
-0.98% (-7,541)
|
|||
|
2020 Q2
|
10.09%
|
$262.98
|
-11.88% (-103,999)
|
|||
|
2020 Q1
|
11.44%
|
$227.04
|
+39.48% (+247,815)
|
|||
|
2019 Q4
|
10.02%
|
$302.03
|
-1.68% (-10,745)
|
|||
|
2019 Q3
|
8.18%
|
$240.10
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.